highly significantP ≤ .0001
Similarly, all nonmyeloablative regimens had highly significant reductions in aGVHD risk ( P ≤ .0001 and P ≤ .0003 for grade 2 to 4 and grade 3 to 4 aGVHD, respectively).
Similarly, all nonmyeloablative regimens had highly significant reductions in aGVHD risk ( P ≤ .0001 and P ≤ .0003 for grade 2 to 4 and grade 3 to 4 aGVHD, respectively).